← back to search

Bo Peng

University of Groningen · NL
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Ferroptosis and cancer prognosis, Cancer, Hypoxia, and Metabolism, and Cancer Research and Treatments.
h-index
30
citations
3,787
works
215
NIH funding
primary concept
Medicine
email

Recent publications

Assessment of glymphatic function and white matter integrity in children with autism using multi-parametric MRI and machine learning
European Radiology 2025cited by 17position: middledoi
Neoadjuvant immunotherapy driven bladder preservation for muscle invasive bladder cancer
iMeta 2025cited by 3position: middledoi
Risk factors predicting the reinfection in periprosthetic joint infection with sinus tracts following prosthesis removal and antibiotic bone cement spacer implantation
Research Square 2025cited by 0position: middledoi
Risk factors predicting the reinfection in periprosthetic joint infection with sinus tracts following prosthesis removal and antibiotic bone cement spacer implantation: a case control study
BMC Infectious Diseases 2025cited by 0position: middledoi
Tumour evolution and microenvironment interactions in 2D and 3D space
Nature 2024cited by 136position: middledoi
KMT2D‐mediated H3K4me1 recruits YBX1 to facilitate triple‐negative breast cancer progression through epigenetic activation of c‐Myc
Clinical and Translational Medicine 2024cited by 15position: middledoi
Exploration oxidative stress underlying gastroesophageal reflux disease and therapeutic targets identification: a multi-omics Mendelian randomization study
Postgraduate Medical Journal 2024cited by 2position: middledoi
Comprehensive analysis of PPP4C’s impact on prognosis, immune microenvironment, and immunotherapy response in lung adenocarcinoma using single-cell sequencing and multi-omics
Frontiers in Immunology 2024cited by 2position: middledoi
Evaluating peritumoral and intratumoral radiomics signatures for predicting lymph node metastasis in surgically resectable non-small cell lung cancer
Frontiers in Oncology 2024cited by 1position: middledoi
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
JAMA 2023cited by 346position: middledoi
Reduced hepatic bradykinin degradation accounts for cold-induced BAT thermogenesis and WAT browning in male mice
Nature Communications 2023cited by 34position: middledoi
Comparison of joint awareness after total knee arthroplasty, medial unicompartmental knee arthroplasty, and high tibial osteotomy: a retrospective study
BMC Musculoskeletal Disorders 2023cited by 13position: middledoi
Single-cell data analysis of malignant epithelial cell heterogeneity in lung adenocarcinoma for patient classification and prognosis prediction
Heliyon 2023cited by 12position: middledoi
Bioinformatics analysis and single-cell RNA sequencing: elucidating the ubiquitination pathways and key enzymes in lung adenocarcinoma
Journal of Thoracic Disease 2023cited by 12position: middledoi
Preoperative computed tomography-based tumoral radiomic features prediction for overall survival in resectable non-small cell lung cancer
Frontiers in Oncology 2023cited by 10position: firstdoi
Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma
Scientific Reports 2023cited by 6position: middledoi
Identification of endoplasmic reticulum stress-related lncRNAs in lung adenocarcinoma by bioinformatics and experimental validation
Annals of Medicine 2023cited by 4position: middledoi
An anoikis-based gene signature for predicting prognosis in malignant pleural mesothelioma and revealing immune infiltration
Journal of Cancer Research and Clinical Oncology 2023cited by 3position: middledoi
Development and validation of a nomogram for predicting overall survival of resected N2 non-small cell lung cancer patients undergoing neoadjuvant radiotherapy
Journal of Cancer Research and Clinical Oncology 2023cited by 2position: middledoi
Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma
Aging 2023cited by 2position: middledoi
Comparison of joint awareness after total knee arthroplasty, medial unicompartmental knee arthroplasty, and high tibial osteotomy: a retrospective study
Research Square 2023cited by 0position: middledoi
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)
Nature Communications 2022cited by 149position: middledoi
Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study
Cell Reports Medicine 2022cited by 137position: middledoi
Identification of Tumor Antigens and Immune Subtypes in Lung Adenocarcinoma for mRNA Vaccine Development
Frontiers in Cell and Developmental Biology 2022cited by 13position: middledoi
Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development
Frontiers in Genetics 2022cited by 9position: middledoi
Mitochondrial Homeostasis–Related lncRNAs are Potential Biomarkers for Predicting Prognosis and Immune Response in Lung Adenocarcinoma
Frontiers in Genetics 2022cited by 6position: firstdoi
Identification of a prognostic index system and tumor immune infiltration characterization for lung adenocarcinoma based on mRNA molecular of pyroptosis
Frontiers in Medicine 2022cited by 6position: middledoi
A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments
Journal of Thoracic Disease 2022cited by 4position: middledoi
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study
Journal of Thoracic Oncology 2021cited by 145position: middledoi
Systematic profiling of ferroptosis gene signatures predicts prognostic factors in esophageal squamous cell carcinoma
Molecular Therapy — Oncolytics 2021cited by 55position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ran Xu · Sun Yat-sen University14 papers (2021–2024)Linyou Zhang · Harbin Medical University10 papers (2021–2024)Tong Lu · Nanjing University of Chinese Medicine10 papers (2021–2023)Xiang Zhou · Harbin Medical University7 papers (2023–2024)Kaiyu Wang · Nanjing University of Chinese Medicine7 papers (2022–2024)Jiaying Zhao · Fudan University7 papers (2021–2024)Chenghao Wang · University of Electronic Science and Technology of China6 papers (2022–2023)Zhiping Shen · Harbin Medical University5 papers (2023–2024)Chengyu Xu · Harbin Medical University5 papers (2023–2024)Linyou Zhang · Sun Yat-sen University Cancer Center4 papers (2021–2024)Xiaoyan Chang · Nanjing University of Chinese Medicine4 papers (2021–2023)Jiaxin Shi · Ningbo University4 papers (2023–2023)Jiaxin Shi · Ningbo University4 papers (2023–2024)Lingqi Yao · Harbin Medical University4 papers (2021–2023)Chenghao Wang · Fudan University3 papers (2022–2024)Yongchao Li · Qiqihar University3 papers (2021–2023)Xiaoyan Chang · Nanjing University of Chinese Medicine3 papers (2023–2024)Xiaoyan Chang · Harbin Medical University3 papers (2022–2023)Shao Q. Yao · National University of Singapore3 papers (2016–2017)Ruisi Na · Harbin Medical University3 papers (2021–2022)